General description
A cell-permeable, reversible inhibitor of nitric oxide synthase in vitro (IC50 = 2-3 µM) and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.
Endogenous reversible inhibitor of nitric oxide synthesis in vitro and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NOS in vitro
Product does not compete with ATP.
Reversible: yes
Target IC50: 2-3 µM inhibiting nitric oxide synthase in vitro
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
Other Notes
Closs, E.I., et al. 1997. Nitric Oxide1, 65.
Faraci, F.M., et al. 1995. Am. J. Physiol.269, H1522.
Gardiner, S.M., et al. 1993. Br. J. Pharmacol. 110, 1457.
Kotani, K., et al. 1992. J. Neurochem.58, 1127.
Vallance, P., et al. 1992. Lancet339, 572.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
| Quality Segment | 100 |
| assay | ≥98% (TLC) |
| form | amorphous solid |
| manufacturer/tradename | Calbiochem® |
| storage condition | OK to freeze,desiccated (hygroscopic) |
| color | white |
| solubility | water: 50 mg/mL |
| shipped in | wet ice |
| storage temp. | −20°C |
| SMILES string | Cl.Cl.N[C@@H](CCCN=C(N(C)C)N)C(=O)O |
| InChI | 1S/C8H18N4O2.2ClH/c1-12(2)8(10)11-5-3-4-6(9)7(13)14;;/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14);2*1H/t6-;;/m0../s1 |
| InChI key | SYLNVYJOPZWPJI-ILKKLZGPSA-N |
